Advertisement

Search Results for "Ventilator Acquired Pneumonia"

03:14 EDT 22nd May 2013 | BioPortfolio

Original Source: Treatment guidelines and outcomes of hospital-acquired and ventilator-associated pneumonia.

Hospital-acquired pneumonia is the second most frequent nosocomial infection and the first in terms of morbidity, mortality, and cost. In recent years, international societies and, most recently, the American Thoracic Society jointly with the Infectious Disease Society of America, have developed guidelines for the management of hospital-acquired pneumonia, health care-associated pneumonia, and ventilator-associated pneumonia. These guidelines include recommendations for risk stratification, initial and defi...

Matching Channels

Pseudomonas aeruginosa Vaccines

Pseudomonas aeruginosa is an opportunistic gram-negative bacteria that lives in soil, water, and even in environments like hot tubs. For most healthy people, this bacteria seldom poses a problem. Pse...

Ventilator settings

Acquired ichthyosis

Acquired immunity

Pneumonia

Matching News

Reducing Ventilator-Associated Pneumonia in the NICU

What strategies can be implemented to decrease ventilator associated pneumonia in the NICU? Infection Control and Hospital Epidemiology

Ventilator-Associated Pneumonia Rises in Long-term Hospitals

CMS data showed increasing rates of ventilator-associated pneumonia at long-term- care hospitals over 5 years, but no differences were seen in mortality among those with and without the infection. M...

[Articles] Attributable mortality of ventilator-associated pneumonia: a meta-analysis of individual patient data from randomised prevention studies

The overall attributable mortality of ventilator-associated pneumonia is 13%, with higher rates for surgical patients and patients with a mid-range severity score at admission. Attributable mortality...

Oral Chlorhexidine for the Prevention of VAP in Children

Does chlorhexidine gel prevent ventilator acquired pneumonia in children? Pediatric Critical Care Medicine

Clinigen and Theravance deal on Vibativ; Cubist expands rights to ceftolozane

UK-based Clinigen Group (LSE: CLIN ) and Theravance (Nasdaq: THRX) of the USA have entered into an exclusive agreement in Europe for Vibativ (telavancin) for the treatment of nosocomial pneumonia (hos...

Simple measures halve ventilator-associated pneumonia

Adding a bundle of low-cost interventions to surveillance significantly reduces rates of ventilator-associated pneumonia in adult intensive care units in developing countries, shows an international s...

High Blood Sugar May Make Pneumonia Deadlier

WEDNESDAY, May 30 (HealthDay News) -- Elevated blood sugar levels may help predict death in pneumonia patients, researchers say. The new study included nearly 6,900 patients, average age 60, with com...

Preventing Ventilator-Associated Pneumonia Does the Evidence Support the Practice? Preventing Ventilator-Associated Pneumonia

Ventilator-associated pneumonia (VAP) is among the most common infections in patients requiring endotracheal tubes with mechanical ventilation. Ventilator-associated pneumonia is associated with incre...

Matching PubMed Articles

Nosocomial Pneumonia in the Intensive Care Unit Acquired during Mechanical Ventilation or Not.

RATIONALE: Most current information on hospital-acquired pneumonia (HAP) is extrapolated from patients with ventilator-associated pneumonia (VAP). No studies evaluated HAP in the intensive care unit (...

Recommendations for improving the design, conduct, and analysis of clinical trials in hospital-acquired pneumonia and ventilator-associated pneumonia.

Overall decisions on the clinical use of new antimicrobials depend on the validity and reliability of the evidence from appropriately designed, conducted, and analyzed clinical trials. Because pneumon...

Challenges in the design and conduct of clinical trials for hospital-acquired pneumonia and ventilator-associated pneumonia: an industry perspective.

Hospital-acquired pneumonia and ventilator-associated pneumonia are associated with high rates of morbidity and mortality and are often caused by drug-resistant pathogens. Trials of potential new agen...

End points in hospital-acquired pneumonia and/or ventilator-associated pneumonia clinical trials: food and drug administration perspective.

Identification of reliable, reproducible, and precise end points for future studies of hospital-acquired and ventilator-associated pneumonia is of paramount importance for approval of new therapeutic...

Use of severity scoring and stratification factors in clinical trials of hospital-acquired and ventilator-associated pneumonia.

Clinical studies of hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) enroll patients with a very wide spectrum of disease, in part, related to the patient and/or host, the c...

Search Whole site using Google

Loading
Search BioPortfolio:
Advertisement
Advertisement
Advertisement Advertisement